Integrated Multi-Omics Analysis for the Identification of Disease-Associated Variations and Prognostic Biomarkers in Triple-Negative Breast Cancer (TNBC)

Read the full article See related articles

Discuss this preprint

Start a discussion What are Sciety discussions?

Listed in

This article is not in any list yet, why not save it to one of your lists.
Log in to save this article

Abstract

Background

Triple-negative breast cancer (TNBC) exhibits high molecular heterogeneity. While multi-omic panels capture disease complexity, translating these profiles into actionable, cost-effective prognostic tools remains analytically challenging.

Objective

To mathematically distill a high-dimensional multi-omic profile into a lean, highly predictive biomarker panel. Furthermore, we aimed to construct, validate, and clinically anchor a prognostic survival nomogram.

Methods

Matched TCGA-BRCA transcriptomic and epigenomic data (n=5546) were integrated utilizing MOFA2. Functional pathways were mapped via the Enrichr database against Reactome, KEGG, and WikiPathways libraries. A machine learning ensemble (LightGBM, Random Forest) optimized the discovery signature. Prognostic stability was validated via Kaplan-Meier stratification, continuous Z-score Multivariate Cox Regression, and Time-Dependent ROC modeling. The tumor microenvironment was profiled via ssGSEA, and immunotherapy checkpoint correlation was assessed. External validation was executed on a microarray cohort (GSE58812).

Results

A 47-gene discovery signature was computationally optimized into a 15-gene clinical panel (Internal AUC = 0.9898). Kaplan-Meier analysis demonstrated profound prognostic separation (p < 0.0001). Multivariate Cox regression confirmed the signature’s independent prognostic value (Hazard Ratio = 10.67, p < 0.001). Immune profiling revealed the signature is driven by tumor-intrinsic factors, showing no significant correlation with local checkpoint expressions like PD-L1 (p = 0.72). External validation achieved an integrated multi-covariate AUC of 0.6874.

Conclusion

This optimized 15-gene signature and the associated clinical-genomic nomogram provide an accurate, independent, and generalizable framework for individualized TNBC survival prediction.

Article activity feed